Miao 2004.

Study characteristics
Methods	Parallel group 9 not allocated (5 in treatment group refused allocation, 4 in the control group refused allocation)
Participants	Country: China Setting: mixed inpatient and outpatient All stroke pathological types, clinical diagnosis plus confirmation by imaging that a relevant lesion was visible, 2 to 8 months after stroke, clear consciousness, no comprehension problem, 1 lesion in 1 hemisphere, normal language comprehension Mood: depression after stroke onset, HAMD score ≥ 20 Participants: 90 randomised, 34 in each group at treatment end Treatment: 34 people, age 58.16 ± 8.49 years, 19 men Control: 34 people, age 62.45 ± 8.24 years, 18 men Exclusion criteria: other organic brain disorders and other aetiologies‐related depression
Interventions	Treatment: citalopram 20 mg daily plus usual stroke care Control: usual stroke care Duration of treatment: 6 weeks Duration of follow‐up (treatment end to study end): 0
Outcomes	HAMD SDS Efficacy Death AEs (only in the citalopram group) Method of recording AEs was not stated
Funding source	Source of funding not stated
Notes	−
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "Simple random sampling" Comment: no further description given
Allocation concealment (selection bias)	Unclear risk	Allocation not described
Blinding of participants and personnel (performance bias) All outcomes	High risk	No placebo
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding described
Incomplete outcome data (attrition bias) All outcomes	High risk	9 not allocated after randomisation, 13 dropouts
Selective reporting (reporting bias)	Unclear risk	No protocol
Other bias	Unclear risk	Baseline balanced